|
Vol 51(2017) N 6 p. 921-926; DOI 10.1134/S0026893317060061  G.A. Efimov1,2,3, J.M.H. Raats4, R.G.S. Chirivi4, J.W.G. van Rosmalen4, S.A. Nedospasov2,3,5* Humanization of Murine Monoclonal anti-hTNF Antibody: The F10 Story 1National Research Center for Hematology, Ministry of Healthcare of the Russian Federation, Moscow, 125167 Russia2Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia 3Moscow State University, Moscow, 119991 Russia 4ModiQuest B.V., 5349 AE Oss The Netherlands 5Lobachevsky University of Nizhny Novgorod, Nizhny Novgorod, 603022 Russia *sergei.nedospasov@gmail.com Received - 2017-06-20; Accepted - 2017-07-21 Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of autoimmune diseases and became one of the most successful examples of the clinical use of monoclonal antibodies. Currently, anti-TNF therapy is used by millions of patients worldwide. At the moment, fully human anti-TNF antibody Adalimumab is the best-selling anti-cytokine drug in the world. Here, we present a story about a highly potent anti-TNF monoclonal antibody initially characterized more than 20 years ago and further developed into chimeric and humanized versions. We present comparative analysis of this antibody with Infliximab and Adalimumab. TNF, tumor necrosis factor, recombinant antibodies, humanized antibodies |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
